Aspeya
Gordon Dawson is a seasoned professional in the pharmaceutical and consumer health sectors, currently serving as the Head of Product Development for Consumer Health at Vectura Fertin Pharma since April 2022. Previously, Gordon held the position of R&D Vice President for Cold and Flu at GSK Consumer Health from June 2015 to March 2022, where responsibilities included defining R&D strategy and overseeing transformative innovation projects. Prior experience at Novartis Consumer Health encompassed roles such as R&D Integration Lead, Vice President of Global Product Development, Director of Global Product Development for Pain, and Head of Product Development at the Nyon site, contributing significantly to product strategy and operational management across global teams. Gordon's career also includes leadership roles at Fournier Pharma and CeNeS Drug Delivery, underscored by a robust academic foundation with a PhD in Pharmaceutical Science and a BSc in Pharmacy from the University of Strathclyde.
This person is not in any teams
This person is not in any offices
Aspeya
We are on a journey to empower healthier lifestyles and target specific unmet needs. We do this by being innovative, optimizing formulas, and applying rigorous scientific standards. This involves harnessing deep insight and scientific substantiation to reimagine how ingredients can be used, and working towards the development and commercialization of a pipeline of wellness and healthcare products and brands. We are applying our expertise to innovate in four areas of focus: Consumer health, cannabinoids, inhaled therapeutics, and nicotine replacement therapy. Our people are open-minded thinkers, leading-edge scientists, and knowledgeable innovators. Want to join our team? Visit our careers site to search for opportunities: careers.aspeya.com